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Recent studies have emphasized an important role for long non-coding RNAs (lncRNA) in
epigenetic regulation, development, and disease. Despite growing interest in lncRNAs,
the mechanisms by which lncRNAs control cellular processes are still elusive. Improved
understanding of these mechanisms is critical, because the majority of the mammalian
genome is transcribed, inmost cases resulting in non-coding RNAproducts. Recent studies
have suggested the involvement of lncRNA in neurobehavioral and neurodevelopmental
disorders, highlighting the functional importance of this subclass of brain-enriched RNAs.
Impaired expression of lnRNAs has been implicated in several forms of intellectual disability
disorders. However, the role of this family of RNAs in cognitive function is largely unknown.
Here we provide an overview of recently identiﬁed mechanisms of neuronal development
involving lncRNAs, and the consequences of lncRNA deregulation for neurodevelopmental
disorders.
Keywords: long non-coding RNA, nervous system development, fragile X syndrome, genomic imprinting, autism
spectrum disorders, intellectual disability, schizophrenia
INTRODUCTION
Therapeutic strategies for the amelioration of neurobehavioral
dysfunction in neurodevelopmental disorders such as intellectual
disabilities (ID), or autism spectrum disorders (ASD) are often
insufﬁcient for a large patient population. These disorders have
complex behavioral and cognitive phenotypes that are thought
to develop through disturbances in neural circuitry and synaptic
function. Moreover, genetic epidemiology and population genetic
studies suggested that a spectrum of allelic risk underlies com-
plex traits like ID (Geschwind, 2008). However, the existence of
risk alleles rarely confers diagnostic speciﬁcity (Hitzemann et al.,
2013). One possible explanation for this may involve dysregula-
tion of the rate of gene transcription/translation by small or long
non-coding (nc)RNAs, leading to abnormal expression of ID-risk
genes of phenotypic relevance (Olde Loohuis et al., 2012). Several
studies have now indicated altered levels of brain-speciﬁc small
and long ncRNA in ID and other neurodevelopmental disorders
(Willemsen et al., 2011). lncRNAs constitute a large fraction of the
total ncRNA pool, each exceeding 200 nucleotides in length. It
was initially assumed that lncRNAs merely act as primary or pre-
cursor transcripts for the production of short ncRNAs (sncRNAs)
such as microRNAs (miRNAs) or small nucleolar RNAs (snoR-
NAs; Aschraﬁ et al., 2008). Conversely to snoRNAs genes, however,
the evolutionary conservation of lncRNAs often extends beyond
the overlapping sncRNA segments (Wang et al., 2004). They have
been shown to either act solely, or together with proteins, exerting
a wide range of cellular roles, e.g., their regulation of transcrip-
tion and RNA processing (Wang et al., 2008). The purpose of
this review is to emphasize the role of lncRNAs in regulating
neuronal molecular pathways, and to highlight their putative
role in dysregulation of these mechanisms in neurodevelopmental
disorders.
MECHANISMS OF ACTION OF lncRNAs
LncRNA TRANSCRIPTION MODULATES THE EXPRESSION OF OTHER
GENES
Transcription of lncRNAs from alternative transcription start sites
in the vicinity of other genes may interfere with the transcrip-
tion efﬁciency of that gene (Martens et al., 2005; Martianov et al.,
2007). These transcriptional interference mechanisms have been
shown to regulate key developmental pathways, such as those
involving Hox-genes expression (Wang et al., 2011). A complete
overview of potential regulatory mechanisms of lncRNAs is pro-
vided in (Guttman and Rinn, 2012) or (Ponting et al., 2009). A
schematic overview of lncRNAs cellular function is depicted in
Figure 1.
LncRNAs MAY REGULATE RNA-PROCESSING AND PROTEIN ACTIVITY
Initial research suggested that the functions of lncRNAs relate to
their interactionswith theRNA-binding proteins (RBPs), a protein
family highly abundant in the brain (Smart et al., 2007). Due to
the long sequence and structural characteristics of lncRNAs, along
with various RBPs and RNA-binding domains, numerous com-
binations of lncRNA/RNA-binding proteins can be formed. This
allows the recruitment of various protein-complexes and a multi-
tude of “downstream” functions. Previous studies suggested that
lncRNAs, in concert with RBPs and different protein-complexes,
have the capacity to induce chromatin remodeling and histone
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FIGURE 1 | An overview of known regulatory mechanisms for lncRNA.
Transcription from an upstream promoter can negatively or positively affect
the expression of a downstream gene via (1) transcriptional interference
mediated by inhibition of RNA Polymerase 2 recruitment, or by (2) inducing
chromatin remodeling and histone modiﬁcation. Alternatively, an antisense
transcript is able to hybridize to the overlapping sense transcript and
modulate further processing (3), or provide a substrate for Dicer, or other
nucleases, in order to generate various small non-coding RNAs (4). By binding
to speciﬁc protein partners, a long noncoding transcript may modulate the
activity of that particular protein (5), serve as a structural component that
allows the formation of a larger RNA–protein complex (6), or alter the cellular
localization of the protein (7).
modiﬁcation, as well as modulating alternative splicing and
protein-activity. For example, Alu RNA and B2 RNA may directly
affect RNA polymerase II activity. Both are transcribed from Short
InterspersedNuclearElements (SINEs;Yakovchuk et al.,2009).Alu
RNA and B2 RNA block binding of RNA polymerase II to the pro-
moter and change the conformation of the transcription initiation
complex signiﬁcantly.
CHROMATIN REMODELING AND HISTONE MODIFICATION CAN BE
INDUCED BY lncRNAs
LncRNAs are capable of mediating the activity of proteins involved
in chromatin remodeling and histone modiﬁcation, including
those at the Polycomb Repressive Complex 2 (PRC2) complex
(Khalil et al., 2009; Tsai et al., 2010) and the CBP/p300 complex
(Wang et al., 2008). A genome-wide study revealed that approx-
imately one third of conserved intergenic lncRNAs associates
with either the PRC2 complex or the CoREST/REST or SCMX
proteins, all known chromatin-modifying proteins (Khalil et al.,
2009). A prominent epigenetic mechanism exerted by lncRNAs
is the X-chromosome inactivation. The extent of this control is
unique among the chromosomes and is disrupted in X-linked
IDs. X-chromosome inactivation is mediated via the lncRNA
Xist that binds to one of the X-chromosomes (Zhao et al., 2008).
RepA was found to be both part of the Xist lncRNA, as well
as expressed by itself (Zhao et al., 2008). The RepA lncRNA is
able to bind the histone methyltransferase Enhancer of Zester
Homolog 2 (Ezh2), which is a subunit of the PRC2. The recruit-
ment of the PRC2 complex by Xist, via the RepA sequence, allows
trimethylation on lysine-27 of H3 histones (H3K27), effectively
repressing gene expression, and inactivating the X-chromosome
(Zhao et al., 2008). Very Recently, Xist was found to function in a
two-step mechanism, though targeting of gene-rich islands before
gene-poor domains (Simon et al., 2013).
FUNCTIONAL ROLES OF lncRNAs IN NERVOUS SYSTEM
DEVELOPMENT AND FUNCTION
Multiple lines of evidence suggest that dysregulated processes as
seen in neurodevelopmental disorders are based on mechanisms
that are under tight regulation by lncRNAs (see below). A number
of ncRNAs were found to be speciﬁcally expressed within the hip-
pocampus (Mercer et al., 2008b), a region involved in processing
and consolidation of memories. Several lncRNAs originate from
genomic regions associated with protein-coding genes involved in
memory formation and maintenance, such as an lncRNA tran-
scribed antisense to Camkk1, which is involved in male-speciﬁc
memory formation (Mercer et al., 2008a).
During brain development, differentiation of neural stem cells
and progenitors is crucial. Recently, various lncRNAs have been
linked to these events, implying a key role for lncRNAs not
only during development, but also in several neuropathologies
(reviewed by e.g., Qureshi et al., 2010). For example, a subset
of lncRNAs are speciﬁcally associated with genes from the Dlx-
family, known to be involved in brain development in mammals
and Drosophila. Two of the differentially expressed lncRNAs,
Evx1as andHox5b/6as were shown to be associated with trimethy-
lated H3K4 histones and histone methyltransferases (Dinger et al.,
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2008). In addition, embryonic ventral forebrain-2 (Evf2) is tran-
scribed from theDlx5/Dlx6 locus, antisense to theDlx6 gene (Feng
et al., 2006). Dlx6 is a homeobox-containing transcription factor
important in forebrain neurogenesis (Stenman et al., 2003). Fur-
thermore, 659 evolutionary conservedmurine lncRNAs have been
identiﬁed of which the brain-speciﬁc lncRNAs are preferentially
(2 to 3-fold increase) located adjacent to brain-expressed protein-
coding genes, involved in transcriptional regulation, or in nervous
system development (Ponjavic et al., 2009).
Recent studies identiﬁed 945 lncRNAs, of which 174 were dif-
ferentially expressed in the mouse embryoid bodies; and that
are annotated to developmentally important events relating to
stem cell pluripotency (Dinger et al., 2008). One of these RNAs,
Sox2OT (Sox2 Overlapping Transcript) is a highly conserved
lncRNA that overlaps the Sox2 gene (Fantes et al., 2003). Sox2
is a transcription-factor critical in maintaining self-renewal prop-
erties of neural stem cells (Mizuseki et al., 1998). Similar to Sox2,
Sox2OT is present in neural stemcells and is downregulated during
differentiation (Amaral et al., 2009).
During fate-speciﬁcation fromneuronal oligodendrocyte bipo-
tent progenitors into GABAergic interneurons, 56 lncRNAs were
found to be upregulated, including Gtl2, Rian, Evf2 and Copg2as,
but also the novel AK044422 (Mercer et al., 2010). Interestingly,
AK044422 overlaps with miR-124a, a highly conserved and highly
expressed brain-speciﬁc miRNA previously implicated in regu-
lating neuronal speciﬁcation and differentiation (Makeyev et al.,
2007; Visvanathan et al., 2007). Synaptogenesis is a pivotal pro-
cess during neuronal development, which is altered in various
neurodevelopmental disorders (reviewed by e.g., (Zoghbi, 2003;
Ecker et al., 2013)). Metastasis-associated lung adenocarcinoma
transcript 1 (Malat1) is an lncRNA that is enriched in nuclear
speckles (Hutchinson et al., 2007; Clemson et al., 2009). There,
it co-localizes with splicing factors to controls the expression of
genes involved in synapse function and synaptogenesis (Bernard
et al., 2010).
LncRNAs ARE INVOLVED IN NEURODEVELOPMENTAL
DISORDERS
Several lncRNAs are either differentially expressed in or associated
with neurodevelopmental disorders, such as Prader–Willi syn-
drome (PWS), Angelman syndrome (AS), ID, and ASD (Table 1).
The role of lncRNAs is possibly best understood in genomic
imprinting disorders such as PWS (Wevrick and Francke, 1997;
Jong et al., 1999) and AS (Runte et al., 2004), both of which fea-
ture learning difﬁculties but otherwise have different symptoms
(further discussed below).
IMPRINTING DISORDERS
Genomic imprinting is mediated by various processes such as
DNA methylation and histone modiﬁcation, but also by ncR-
NAs (Bartolomei, 2009). PWS (MIM 176270) is characterized
by infantile hypotonia, early childhood obesity, short stature,
hypogenitalism/hypogonadism, ID, and other behavioral prob-
lems including temper tantrums. The genetic cause of the disorder
lies in a disruption of the paternal chromosome 15q11.2q13, since
the maternal chromosome is inactive through imprinting (Hors-
themke and Wagstaff, 2008). To date, two genes have functionally
been associated with the pathology of the disorder: NECDIN and
small nuclear ribonucleoprotein polypeptide N (SNRPN). Necdin
deﬁcientmice show a subset of themultiple clinicalmanifestations
of PWS (Muscatelli et al., 2000). SNRPN encodes the SmN splicing
factor, the SNRPNupstream reading frame (SNURF) and partially
overlaps the UBE3A gene. Importantly, the downstream introns
of SNRPN contain C/D box-containing SNORD116 (HBII-85)
snoRNA clusters whose expression is under control of the SNRPN
promoter (Runte et al., 2001). Several case reports indicated that
paternally inherited microdeletions of this cluster cause PWS
(Sahoo et al., 2008; de Smith et al., 2009; Duker et al., 2010). More-
over, two mouse models with targeted deletions in the MBII-85
snoRNA cluster exhibited a similar phenotype as other PWSmod-
els, which included decreased activity, hypotonia at birth, and
postnatal growth retardation (Skryabin et al., 2007; Ding et al.,
2008).
IPW (Imprinted gene in the PWS region) is located in the
proximal chromosome 15q, merely 150 kb distal to SNRPN and is
not expressed in patients with 15q11-q13 deletions (Wevrick et al.,
1994). Additionally, ZNF127 is located in the same region and has
been reported to have a disrupted expression in PWS. This gene
has a potentially non-coding antisense gene, ZNF127AS, which
might be regulating the imprinting of ZNF127 gene (Jong et al.,
1999).
Angelman syndrome (MIM 105830) is caused by a disrup-
tion of the maternal allele of chromosome 15q11-q13, covering
the same genomic location as PWS. However, the symptoms
are different and include intellectual disability, movement or
balance disorder, typical abnormal behaviors, and severe lim-
itations in speech and language. The genetic underpinning
of the disorder is thought to be a disruption in the UBE3A
gene (Matsuura et al., 1997). The UBE3A-AS gene is tran-
scribed antisense to the UBE3A gene and repression of UBE3A
is dependent on UBE3A-AS (Chamberlain and Brannan, 2001;
Johnstone et al., 2006). However, another study suggests that
silencing of the paternal UBE3A can also occur when UBE3A-
AS is not present, indicating that the regulation is more complex
(Le Meur et al., 2005).
INTELLECTUAL DISABILITY
Despite the highly variable genetic etiology in ID, only a lim-
ited number of molecular and cellular pathways appear to be
affected by the magnitude of different gene mutations. ID genes
have been shown to cluster in pathways underlying neurogene-
sis, neural migration, neuronal outgrowth, and synaptic function
(van Bokhoven, 2011). Numerous studies have suggested that
synaptogenesis and normal synaptic function is dependent on the
activity of a large number of proteins, and that disturbance of
individual components within the network, or alterations of their
activities causes synaptic dysfunction, phenotypically culminat-
ing in ID (Aschraﬁ et al., 2005). Regulation of gene transcripts
by small and large ncRNAs may underlie epigenetic control of
synaptic activity in ID and other neurodevelopmental disorders.
Previous studies have indicated that disruption of lncRNA expres-
sion and signaling impairs synaptic plasticity, and results in severe
cognitive impairment in mice, and human, which are detailed
below.
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Table 1 | An overview of the lncRNAs identified in neurodevelopmental disorders.
Disorder LncRNA Significance Reference
PWS SNORD116 (HBII-85)
C/D box cluster
Microdeletions including this cluster cause PWS (phenotype) Duker et al. (2010), Sahoo et al. (2008),
de Smith et al. (2009)
IPW Not expressed in PWS Wevrick et al. (1994)
ZNF127AS Disrupted expression in PWS Jong et al. (1999)
AS UBE3A-AS Increased or decreased expression in AS Runte et al. (2004)
FXS FRM4 (FMR1-AS1) Silenced in FXS patients; knockdown results in alterations in cell
cycle regulation and increased apoptotic cell death
Ladd et al. (2007), Khalil et al. (2008)
BC1 Associated with fragile X syndrome Zalfa et al. (2003, 2005)
Rett syndrome AK087060
AK081227
Upregulated in MECP2 KO mice; AK087060 associated with the
downregulation of its host gene, GABA receptor subunit Rho 2
(Gabbr2)
Petazzi et al. (2013)
DS NRON Regulates nuclear shutting of NFAT, whose reduced activity leads
to DS features





FLJ16341 In critical region with three protein-coding genes: BCL11A,
PAPOLG, and REL
Hancarova et al. (2013)
MCOPS3 SOX2OT Modulates expression of SOX2, in which genetic defects cause
micropthalmia syndrome 3.
Fantes et al. (2003), Amaral et al. (2009)






Deletions are only found in males with ASD and not in male
control individuals.
Noor et al. (2010)
The disorders are listed in the ﬁrst column (PWS, Prader–Willi syndrome; AS, Angelmann syndrome; FXS, fragile X syndrome; DS, down syndrome; MCOPS3,
micropthalmia syndrome 3; ASD, autism spectrum disorder).
Fragile X Syndrome
Fragile X syndrome (FXS, MIM 300624) is inherited via an
X-linked dominant pattern and characterized by moderate to
severe mental retardation, macro-orchidism, and distinct facial
features. The disorder is caused by an unstable expansion of a
CGG repeat in the FMR1 gene leading to silencing of the gene
by methylation of repeat and promoter (Sutcliffe et al., 1992),
resulting in decreased FMRP protein levels in the brain (Devys
et al., 1993). Accumulating evidence suggests that the etiology of
the disorder is inﬂuenced by lncRNAs. The promoter of FMR1
is bidirectional and can also give rise to the lncRNA FMR4 or
FMR1-AS1, a gene transcribed in the antisense orientation and
overlaps the CGG repeat region. FMR4 is similar to FRM1 in being
silenced in FXS patients and upregulated in permutation carriers
(Ladd et al., 2007; Khalil et al., 2008). Following siRNAknockdown
of FMR4, alterations in cell cycle and apoptosis were reported.
Conversely, overexpression of FMR4 resulted in increased cell
proliferation. Additionally, knockdown of FMR4 did not inﬂu-
ence FMR1 expression and vice versa, suggesting an independent
mechanism from FMR1 (Khalil et al., 2008). Together, these
ﬁndings points toward a contribution of FMR4 in the pathology
of FXS.
Recently, Pastori et al. (2013) discovered two new transcripts
in the FMR1 gene locus: FMR5 and FMR6. FMR5 was similarly
expressed in brain regions from unaffected and permutation indi-
viduals and full mutation patients, whereas FMR6 was silenced
in full mutation and permutation carriers. According to the
authors, this might suggest an abnormal transcription or chro-
matin remodeling prior to transition to the full mutation. In
addition to the ﬁnding that both FMR5 and FMR6 are expressed
in blood leukocytes, these lncRNAs are potentially useful as
biomarkers in FXS.
FMRP, the protein that is encoded by FMR1, acts as a transla-
tional repressor of speciﬁc mRNAs at the synapse and associates
with the dendritic RNA BC1 (Zalfa et al., 2003). BC1 enables
the interaction of FMRP with the target mRNAs; and FMRP
can directly bind to BC1 and its human analog BC200 via its
N-terminus. Of note, the 5′ stem loop of BC1 is involved in
FMRP recognition and this region is complementary to FMRP
target mRNAs (Zalfa et al., 2005). Taken together, the stud-
ies suggested that BC1 is a ncRNA that is essential for the
repression of mRNAs via FMRP and loss of this repression in
FXS patients could result in synaptic dysfunction. It should be
noted that, In Iacoangeli et al. (2008), ﬁve independent groups
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reported that results published by Zalfa et al. (2003) are not
reproducible. Thus, there is no conﬁrmation, independent of
the Bagni group, of a speciﬁc physical link between FMRP and
BC1 RNA.
Rett syndrome
Rett syndrome (MIM 312750) is characterized by arrested devel-
opment between 6 and 18 months of age in females, regression of
acquired skills, loss of speech, stereotypical movements, seizures,
and ID. Mutations in the MECP2, which binds methylated
CpGs and can both activate and repress transcription, were ﬁrst
described to be the cause of the disorder (Amir et al., 1999). While
assessing the transcriptome of male Mecp2 hemizygous knockout
mouse brains (Petazzi et al., 2013), it was revealed that the lncRNAs
AK081227 and AK087060 were both signiﬁcantly upregulated as
compared to wild-type littermates. Importantly, overexpression of
AK08127 was associated with the downregulation of its host cod-
ing protein gene, the gamma-aminobutyric acid receptor subunit
Rho 2. This suggest that transcriptional dysregulation of lncR-
NAs may have the capacity to contribute to the etiology of Rett
syndrome.
Down syndrome
Down syndrome (DS) or Trisomy 21 (MIM 190685) is charac-
terized by ID, distinct facial characteristics and congenital heart
defects. The lncRNA NRON may be involved in DS, since
NRON modulates cytoplasmic-to-nuclear transport of NFAT
(Willingham et al., 2005). Decreased nuclear NFAT activity leads
to DS-like characteristics in animal models, suggesting a pos-
sible role for NRON in DS (Arron et al., 2006). Recently, an
inducible XIST was introduced on chromosome 21 using genome
editing (Jiang et al., 2013). This approach created a model to
investigate genomic expression changes and cellular pathologies
of trisomy 21. Notably, deﬁcits in proliferation and neural rosette
formation are rapidly reversed upon silencing one chromosome
21, representing a major step toward potential development of
“chromosome therapy” (see Figure 2 for a proposed approach).
Other syndromic neurodevelopmental disorders
In the last decade, several new rare microdeletion syndromes were
identiﬁed. One of these is the 2p15-p16.1microdeletion syndrome
(Rajcan-Separovic et al., 2007), characterized by ID, autistic fea-
tures, microcephaly, short stature, and various dysmorphic facial
features. The genomic cause of this disorder remains to be elu-
cidated, but the susceptibility candidate genes include BCL11A,
PAPOLG and REL and one lncRNA gene FLJ16341, although the
function of this lncRNA is still elusive.
AUTISM SPECTRUM DISORDER
Autism spectrum disorders is an umbrella term for various devel-
opmental disorders, including autism, pervasive developmental
disorder not otherwise speciﬁed (PDD-NOS) and the Asperger
syndrome. Common symptoms of the various ASD disorders
include problems of reciprocal social interactions, verbal and
non-verbal communication, and rigid and stereotyped behav-
iors. ASD is a clinically and etiologically heterogeneous disorder
with a complex genetic architecture. Not only multiple common
genetic variants appear to be involved, each with small effect
size, but also rare variants with strong effect size (Devlin and
Scherer, 2012). The latter are mostly de novo mutations, as evi-
denced by whole-exome and genome sequencing studies in ASD
patients (Talkowski et al., 2012; Vulto-van Silfhout et al., 2013), or
copy number variations (CNVs; Poelmans et al., 2013). Microar-
ray analysis shows that 5–10% of subjects with ASD have an
identiﬁable genetic etiology in recurrent or de novo chromoso-
mal rearrangements (Marshall et al., 2008). In the last decade,
several studies reported aberrant expression of lncRNAs, sug-
gesting that these might be important in the etiology of the
disorder. Recently, Ziats and Rennert (2013) showed that over
200 lncRNAs were differentially expressed in amicroarray of post-
mortem prefrontal cortex and cerebellum tissue of ASD patients.
A decade earlier, Vincent et al. (2002) identiﬁed a novel autism
locus, which includes the gene RAY1/ST7. This locus contains
at least four non-coding genes (ST7OT1-4), both on the sense
and antisense strands that potentially regulate RAY1/ST7. Sev-
eral rare variants were detected in autism patients on either the
RAY1/ST7 or the ST7OT1-3 genes that were not observed in a
control population.
Mutations in the X-chromosome PTCHD1 gene have been
reported to involve X-linked ID and ASD (Noor et al., 2010;
Filges et al., 2011). Although the exact function of the gene is
still unknown, several lines of evidence suggest that it might
have a causative role in a subset of ID and/or ASD patients
(Filges et al., 2011). On the antisense strand of the PTCHD1
gene, several overlapping lncRNAs (PTCHD1AS1, PTCHD1AS2
and PTCHD1AS3) were detected, which may serve as regula-
tors for PTCHD1, since the 5′ exons are adjacent on opposite
strands.
CONCLUSION
Regulation of epigenetics processes during brain development and
in activity-dependent brain functions are key to the symptomol-
ogy underlying many neurodevelopmental disorders. In recent
time, a wide range of cutting-edge “omics” and bioinformatics
based technologies vastly accelerated our understanding of the
key molecular players and mechanisms involved in regulating
these epigenetic processes. In contrast to the earlier held view
that lncRNAs were merely transcriptional noise, it is now appar-
ent that lncRNAs exert important regulatory functions in the
brain, both during adult and developmental stages and repre-
sent a key epigenetic mediator of these processes. The interplay
between lncRNAs and chromatin remodeling factors may be
key to understanding the role of epigenetics in neurodevelop-
mental disorders (Kramer and van Bokhoven, 2009). LncRNAs
are now believed to modulate molecular events during neuro-
genesis, cell-fate decisions, differentiation and maturation, but
are also involved in higher brain functions such as memory
formation. The large number of brain-expressed lncRNAs sug-
gests that many more such higher-order functions might also
be modulated by lncRNA-mediated mechanisms, which remain
to be more fully illustrated in future research efforts. Animal
models of lncRNA function, e.g. knockout mice for Malat1
(Zhang et al., 2012) and Neat1 (Nakagawa et al., 2011), have
been developed recently and might provide a better insight in
lncRNA-mediated mechanisms. However, already at this stage it
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FIGURE 2 | Proposed strategy for a therapeutic application of Xist and
zinc finger nucleases (ZFN) to treat trisomy 21. Adeno-associated viruses
(AAVs) are currently the most promising CNS gene delivery vector (for review,
see Gray, 2013). As shown in this scheme, the ﬁrst step in the approach
would be incorporation of plasmids containing Xist and ZFN targeted to the
DYRK1A locus on chromosome 21 in AAVs (1). Next, injection of the viruses
in rodents can be performed intracranial, intravenous or in the cerebrospinal
ﬂuid (2). Intracranial injections have been successfully performed in mammals
as large as cats, but an estimated number of 20–30 required injections per
hemisphere in human infants rendered this technique unfavorable over
alternatives (Vite et al., 2005). AAV9 vectors have the capacity to cross the
blood-brain barrier and transduce neurons and astrocytes (Foust et al., 2009),
making intravascular injection of viral vectors for CNS targeted gene therapy a
possibility. The third possible route of administration is injecting the viral
vectors in the cerebrospinal ﬂuid (CSF), thus transducing the central nervous
system effectively even in non-human primates (Samaranch et al., 2012). After
injection of the AAVs and transduction of the viruses in the cells, Xist will be
incorporated on the ZFN target site in the DYRK1A locus on chromosome 21
(3). Here, it will induce the formation of a chromosome 21 Barr body (4),
which will lead to gene silencing and hypermethylation of promoter CPG
islands, effectively stabilizing the inactivation of the chromosome (5; Jiang
et al., 2013). Eventually, this approach may lead to a CNS-wide inactivation of
the third chromosome 21, thereby reducing the symptoms of the trisomy 21
disorder. However, several major limitations have to be overcome in order to
translate this proposed approach to humans. First, the optimal age for the
therapeutic intervention should be established. The majority of the in vivo
gene therapy studies have been performed in juvenile or adult animals, but
starting the treatment at an earlier age should be considered in order to
achieve the best therapeutic effect. Moreover, the optimal route of delivery
for CNS gene therapy is currently not established yet, with possibilities being
intravascular injection, injection in the CSF, and to a lesser extend, intracranial
injections. Third, a practical issue of using AAVs in the therapeutic approach is
the limitation of AAVs to contain vectors up to only 4.7 kb in length. This is
insufﬁcient for the Xist containing vector used in the proof-of-principle study
by Jiang et al. (2013). Last, comparing intravascular injection of vectors with a
CNS target revealed that both neuronal and overall transduction efﬁciency in
primates is considerably lower than in rodents, the latter most likely due to
circulating pre-existing neutralizing AAV antibodies (Gray et al., 2011).
is clear that lncRNAs may offer a unique approach to modulate
pathogenetic events in the causation of neurodevelopmental
disorders.
ACKNOWLEDGMENTS
The research of the authors is supported by fundings from
the European Community’s Seventh Framework Programme
(FP7/2007-2013) under grant agreement no. 278948, and the
Marie Curie International Reintegration Grant.
REFERENCES
Amaral, P. P., Neyt, C., Wilkins, S. J., Askarian-Amiri, M. E., Sunkin, S. M.,
Perkins, A. C., et al. (2009). Complex architecture and regulated expression
of the Sox2ot locus during vertebrate development. RNA 15, 2013–2027. doi:
10.1261/rna.1705309
Frontiers in Molecular Neuroscience www.frontiersin.org December 2013 | Volume 6 | Article 53 | 6
“fnmol-06-00053” — 2013/12/26 — 15:15 — page 7 — #7
van De Vondervoort et al. Long non-coding RNAs in neurodevelopmental disorders
Amir, R. E., Van DenVeyver, I. B.,Wan,M., Tran, C. Q., Francke, U., and Zoghbi, H.
Y. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encod-
ing methyl-CpG-binding protein 2. Nat. Genet. 23, 185–188. doi: 10.1038/
13810
Arron, J. R.,Winslow, M. M., Polleri, A., Chang, C. P.,Wu, H., Gao, X., et al. (2006).
NFATdysregulationby increaseddosage of DSCR1 andDYRK1Aon chromosome
21. Nature 441, 595–600. doi: 10.1038/nature04678
Aschraﬁ, A., Cunningham, B. A., Edelman, G. M., and Vanderklish, P. W. (2005).
The fragile X mental retardation protein and group I metabotropic glutamate
receptors regulate levels of mRNA granules in brain 8. Proc. Natl. Acad. Sci.
U.S.A. 102, 2180–2185. doi: 10.1073/pnas.0409803102
Aschraﬁ, A., Schwechter, A. D., Mameza, M. G., Natera-Naranjo, O., Gioio, A. E.,
and Kaplan, B. B. (2008). MicroRNA-338 regulates local cytochrome c oxidase IV
mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons.
J. Neurosci. 28, 12581–12590. doi: 10.1523/JNEUROSCI.3338-08.2008
Bartolomei, M. S. (2009). Genomic imprinting: employing and avoiding epigenetic
processes. Genes Dev. 23, 2124–2133. doi: 10.1101/gad.1841409
Bernard, D., Prasanth, K. V., Tripathi, V., Colasse, S., Nakamura, T., Xuan,
Z., et al. (2010). A long nuclear-retained non-coding RNA regulates synap-
togenesis by modulating gene expression. EMBO J. 29, 3082–3093. doi:
10.1038/emboj.2010.199
Chamberlain, S. J., and Brannan, C. I. (2001). The Prader-Willi syndrome
imprinting center activates the paternally expressed murine Ube3a anti-
sense transcript but represses paternal Ube3a. Genomics 73, 316–322. doi:
10.1006/geno.2001.6543
Clemson, C. M., Hutchinson, J. N., Sara, S. A., Ensminger, A. W., Fox, A. H., Chess,
A., et al. (2009). An architectural role for a nuclear noncoding RNA: NEAT1
RNA is essential for the structure of paraspeckles. Mol. Cell 33, 717–726. doi:
10.1016/j.molcel.2009.01.026
de Smith, A. J., Purmann, C., Walters, R. G., Ellis, R. J., Holder, S. E., Van Haelst,
M. M., et al. (2009). A deletion of the HBII-85 class of small nucleolar RNAs
(snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum.
Mol. Genet. 18, 3257–3265. doi: 10.1093/hmg/ddp263
Devlin, B., and Scherer, S. W. (2012). Genetic architecture in autism spec-
trum disorder. Curr. Opin. Genet. Dev. 22, 229–237. doi: 10.1016/j.gde.2012.
03.002
Devys, D., Lutz, Y., Rouyer, N., Bellocq, J. P., and Mandel, J. L. (1993). The
FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal
in carriers of a fragile X premutation. Nat. Genet. 4, 335–340. doi: 10.1038/
ng0893-335
Ding, F., Li, H. H., Zhang, S., Solomon, N. M., Camper, S. A., Cohen, P.,
et al. (2008). SnoRNA Snord116 (Pwcr1/MBII-85) deletion causes growth deﬁ-
ciency and hyperphagia in mice. PLoS ONE 3:e1709. doi: 10.1371/journal.pone.
0001709
Dinger, M. E., Amaral, P. P., Mercer, T. R., Pang, K. C., Bruce, S. J., Gardiner, B. B.,
et al. (2008). Long noncoding RNAs in mouse embryonic stem cell pluripotency
and differentiation. Genome Res. 18, 1433–1445. doi: 10.1101/gr.078378.108
Duker, A. L., Ballif, B. C., Bawle, E. V., Person, R. E., Mahadevan, S., Alliman, S.,
et al. (2010). Paternally inherited microdeletion at 15q11.2 conﬁrms a signiﬁcant
role for the SNORD116 C/D box snoRNA cluster in Prader-Willi syndrome. Eur.
J. Hum. Genet. 18, 1196–1201. doi: 10.1038/ejhg.2010.102
Ecker, C., Spooren, W., and Murphy, D. G. (2013). Translational approaches to the
biology of Autism: false dawn or a new era? Mol. Psychiatry 18, 435–442. doi:
10.1038/mp.2012.102
Fantes, J., Ragge, N. K., Lynch, S. A.,Mcgill, N. I., Collin, J. R., Howard-Peebles, P. N.,
et al. (2003). Mutations in SOX2 cause anophthalmia. Nat. Genet. 33, 461–463.
doi: 10.1038/ng1120
Feng, J., Bi, C., Clark, B. S., Mady, R., Shah, P., and Kohtz, J. D. (2006). The Evf-
2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and
functions as a Dlx-2 transcriptional coactivator. Genes Dev. 20, 1470–1484. doi:
10.1101/gad.1416106
Filges, I., Rothlisberger, B., Blattner, A., Boesch, N., Demougin, P., Wenzel, F., et al.
(2011). Deletion inXp22.11: PTCHD1 is a candidate gene forX-linked intellectual
disability with or without autism. Clin. Genet. 79, 79–85. doi: 10.1111/j.1399-
0004.2010.01590.x
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., and Kaspar,
B. K. (2009). IntravascularAAV9preferentially targets neonatal neurons and adult
astrocytes. Nat. Biotechnol. 27, 59–65. doi: 10.1038/nbt.1515
Geschwind, D. H. (2008). Autism: many genes, common pathways? Cell 135, 391–
395. doi: 10.1016/j.cell.2008.10.016
Gray, S. J. (2013). Gene therapy and neurodevelopmental disorders. Neuropharma-
cology 68, 136–142. doi: 10.1016/j.neuropharm.2012.06.024
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., and Samulski, R.
J. (2011). Preclinical differences of intravascular AAV9 delivery to neurons and
glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19,
1058–1069. doi: 10.1038/mt.2011.72
Guttman, M., and Rinn, J. L. (2012). Modular regulatory principles
of large non-coding RNAs. Nature 482, 339–346. doi: 10.1038/nature
10887
Hancarova, M., Simandlova, M., Drabova, J., Mannik, K., Kurg, A., and Sedlacek, Z.
(2013). A patient with de novo 0.45 Mb deletion of 2p16.1: the role of BCL11A,
PAPOLG, REL, and FLJ16341 in the 2p15-p16.1 microdeletion syndrome. Am. J.
Med. Genet. A 161A, 865–870. doi: 10.1002/ajmg.a.35783
Hitzemann, R., Bottomly, D., Darakjian, P., Walter, N., Iancu, O., Searles, R.,
et al. (2013). Genes, behavior and next-generation RNA sequencing. Genes Brain
Behav. 12, 1–12. doi: 10.1111/gbb.12007
Horsthemke, B., and Wagstaff, J. (2008). Mechanisms of imprinting of the
Prader-Willi/Angelman region. Am. J. Med. Genet. A 146A, 2041–2052. doi:
10.1002/ajmg.a.32364
Hutchinson, J. N., Ensminger, A. W., Clemson, C. M., Lynch, C. R., Lawrence, J.
B., and Chess, A. (2007). A screen for nuclear transcripts identiﬁes two linked
noncoding RNAs associated with SC35 splicing domains. BMC Genomics 8:39.
doi: 10.1186/1471-2164-8-39
Iacoangeli, A., Rozhdestvensky, T. S., Dolzhanskaya, N., Tournier, B., Schutt, J.,
Brosius, J., et al. (2008). On BC1 RNA and the fragile X mental retardation
protein. Proc. Natl. Acad. Sci. U.S.A. 105, 734–739. doi: 10.1073/pnas.07109
91105
Jiang, J., Jing, Y., Cost, G. J., Chiang, J. C., Kolpa, H. J., Cotton, A. M., et al.
(2013). Translating dosage compensation to trisomy 21. Nature 500, 296–300.
doi: 10.1038/nature12394
Johnstone, K. A., Dubose, A. J., Futtner, C. R., Elmore, M. D., Brannan, C.
I., and Resnick, J. L. (2006). A human imprinting centre demonstrates con-
served acquisition but diverged maintenance of imprinting in a mouse model
for Angelman syndrome imprinting defects. Hum. Mol. Genet. 15, 393–404. doi:
10.1093/hmg/ddi456
Jong, M. T., Gray, T. A., Ji, Y., Glenn, C. C., Saitoh, S., Driscoll, D. J., et al. (1999).
A novel imprinted gene, encoding a RING zinc-ﬁnger protein, and overlapping
antisense transcript in the Prader-Willi syndrome critical region. Hum. Mol.
Genet. 8, 783–793. doi: 10.1093/hmg/8.5.783
Khalil, A. M., Faghihi, M. A., Modarresi, F., Brothers, S. P., and Wahlest-
edt, C. (2008). A novel RNA transcript with antiapoptotic function is
silenced in fragile X syndrome. PLoS ONE 3:e1486. doi: 10.1371/journal.pone.
0001486
Khalil, A. M., Guttman, M., Huarte, M., Garber, M., Raj, A., Rivea
Morales, D., et al. (2009). Many human large intergenic noncoding RNAs
associate with chromatin-modifying complexes and affect gene expression.
Proc. Natl. Acad. Sci. U.S.A. 106, 11667–11672. doi: 10.1073/pnas.09047
15106
Kramer, J. M., and van Bokhoven, H. (2009). Genetic and epigenetic
defects in mental retardation. Int. J. Biochem. Cell Biol. 41, 96–107. doi:
10.1016/j.biocel.2008.08.009
Ladd, P. D., Smith, L. E., Rabaia, N. A., Moore, J. M., Georges, S. A., Hansen, R. S.,
et al. (2007). An antisense transcript spanning the CGG repeat region of FMR1
is upregulated in premutation carriers but silenced in full mutation individuals.
Hum. Mol. Genet. 16, 3174–3187. doi: 10.1093/hmg/ddm293
Le Meur, E., Watrin, F., Landers, M., Sturny, R., Lalande, M., and Muscatelli, F.
(2005). Dynamic developmental regulation of the large non-coding RNA associ-
ated with the mouse 7C imprinted chromosomal region. Dev. Biol. 286, 587–600.
doi: 10.1016/j.ydbio.2005.07.030
Makeyev, E. V., Zhang, J., Carrasco, M. A., and Maniatis, T. (2007). The MicroRNA
miR-124 promotes neuronal differentiation by triggering brain-speciﬁc alter-
native pre-mRNA splicing. Mol. Cell 27, 435–448. doi: 10.1016/j.molcel.2007.
07.015
Marshall, C. R., Noor, A.,Vincent, J. B., Lionel, A. C., Feuk, L., Skaug, J., et al. (2008).
Structural variation of chromosomes in autism spectrum disorder. Am. J. Hum.
Genet. 82, 477–488. doi: 10.1016/j.ajhg.2007.12.009
Frontiers in Molecular Neuroscience www.frontiersin.org December 2013 | Volume 6 | Article 53 | 7
“fnmol-06-00053” — 2013/12/26 — 15:15 — page 8 — #8
van De Vondervoort et al. Long non-coding RNAs in neurodevelopmental disorders
Martens, J. A., Wu, P.-Y. J., and Winston, F. (2005). Regulation of an intergenic
transcript controls adjacent gene transcription in Saccharomyces cerevisiae. Genes
Dev. 19, 2695–2704. doi: 10.1101/gad.1367605
Martianov, I., Ramadass, A., Serra Barros, A., Chow, N., and Akoulitchev, A.
(2007). Repression of the human dihydrofolate reductase gene by a non-coding
interfering transcript. Nature 445, 666–670. doi: 10.1038/nature05519
Matsuura, T., Sutcliffe, J. S., Fang, P., Galjaard, R. J., Jiang, Y. H., Benton, C. S., et al.
(1997). De novo truncating mutations in E6-AP ubiquitin-protein ligase gene
(UBE3A) in Angelman syndrome. Nat. Genet. 15, 74–77. doi: 10.1038/ng0197-74
Mercer, T. R., Dinger, M. E., Mariani, J., Kosik, K. S., Mehler, M. F., and Mattick, J.
S. (2008a). Noncoding RNAs in long-termmemory formation. Neuroscientist 14,
434–445. doi: 10.1177/1073858408319187
Mercer, T. R., Dinger, M. E., Sunkin, S. M., Mehler, M. F., and Mattick, J. S. (2008b).
Speciﬁc expression of long noncoding RNAs in themouse brain. Proc. Natl. Acad.
Sci. U.S.A. 105, 716–721. doi: 10.1073/pnas.0706729105
Mercer, T. R., Qureshi, I. A., Gokhan, S., Dinger, M. E., Li, G., Mattick,
J. S., et al. (2010). Long noncoding RNAs in neuronal-glial fate speciﬁ-
cation and oligodendrocyte lineage maturation. BMC Neurosci. 11:14. doi:
10.1186/1471-2202-11-14
Mizuseki, K., Kishi, M., Matsui, M., Nakanishi, S., and Sasai, Y. (1998). Xenopus
Zic-related-1 and Sox-2, two factors induced by chordin, have distinct activities
in the initiation of neural induction. Development 125, 579–587.
Muscatelli, F., Abrous, D. N., Massacrier, A., Boccaccio, I., Le Moal, M., Cau, P.,
et al. (2000). Disruption of the mouse Necdin gene results in hypothalamic and
behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum.
Mol. Genet. 9, 3101–3110. doi: 10.1093/hmg/9.20.3101
Nakagawa, S., Naganuma, T., Shioi, G., and Hirose, T. (2011). Paraspeckles are
subpopulation-speciﬁc nuclear bodies that are not essential in mice. J. Cell Biol.
193, 31–39. doi: 10.1083/jcb.201011110
Noor, A., Whibley, A., Marshall, C. R., Gianakopoulos, P. J., Piton, A., Carson,
A. R., et al. (2010). Disruption at the PTCHD1 Locus on Xp22.11 in Autism
spectrum disorder and intellectual disability. Sci. Transl. Med. 2, 49ra68. doi:
10.1126/scitranslmed.3001267
Olde Loohuis, N. F., Kos, A., Martens, G. J., Van Bokhoven, H., Nadif Kasri, N.,
and Aschraﬁ, A. (2012). MicroRNA networks direct neuronal development and
plasticity. Cell. Mol. Life Sci. 69, 89–102. doi: 10.1007/s00018-011-0788-1
Pastori, C., Peschansky, V. J., Barbouth, D., Mehta, A., Silva, J. P., andWahlestedt, C.
(2013). Comprehensive analysis of the transcriptional landscape of the human
FMR1 gene reveals two new long noncoding RNAs differentially expressed in
Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. Human
Genet. doi: 10.1007/s00439-013-1356-6 [Epub ahead of print].
Petazzi, P., Sandoval, J., Szczesna, K., Jorge, O. C., Roa, L., Sayols, S., et al. (2013).
Dysregulation of the long non-coding RNA transcriptome in a Rett syndrome
mouse model. RNA Biol. 10, 1197–1203. doi: 10.4161/rna.24286
Poelmans, G., Franke, B., Pauls, D. L., Glennon, J. C., and Buitelaar, J. K. (2013).
AKAPs integrate genetic ﬁndings for autism spectrumdisorders.Transl. Psychiatry
3, e270. doi: 10.1038/tp.2013.48
Ponjavic, J., Oliver, P. L., Lunter, G., and Ponting, C. P. (2009). Genomic and
transcriptional co-localization of protein-coding and long non-coding RNA
pairs in the developing brain. PLoS Genet. 5:e1000617: doi: 10.1371/jour-
nal.pgen.1000617
Ponting, C. P., Oliver, P. L., and Reik, W. (2009). Evolution and functions of long
noncoding RNAs. Cell 136, 629–641. doi: 10.1016/j.cell.2009.02.006
Qureshi, I. A., Mattick, J. S., and Mehler, M. F. (2010). Long non-coding
RNAs in nervous system function and disease. Brain Res. 1338, 20–35. doi:
10.1016/j.brainres.2010.03.110
Rajcan-Separovic, E., Harvard, C., Liu, X., Mcgillivray, B., Hall, J. G., Qiao, Y., et al.
(2007). Clinical andmolecular cytogenetic characterisation of a newly recognised
microdeletion syndrome involving 2p15-16.1. J. Med. Genet. 44, 269–276. doi:
10.1136/jmg.2006.045013
Runte, M., Huttenhofer, A., Gross, S., Kiefmann, M., Horsthemke, B., and Buiting,
K. (2001). The IC-SNURF-SNRPN transcript serves as a host for multiple small
nucleolar RNA species and as an antisense RNA for UBE3A. Hum. Mol. Genet.
10, 2687–2700. doi: 10.1093/hmg/10.23.2687
Runte, M., Kroisel, P. M., Gillessen-Kaesbach, G., Varon, R., Horn, D., Cohen,
M. Y., et al. (2004). SNURF-SNRPN and UBE3A transcript levels in patients
with Angelman syndrome. Hum. Genet. 114, 553–561. doi: 10.1007/s00439-004-
1104-z
Sahoo, T., Del Gaudio, D., German, J. R., Shinawi, M., Peters, S. U., Person, R.
E., et al. (2008). Prader-Willi phenotype caused by paternal deﬁciency for the
HBII-85 C/D box small nucleolar RNA cluster. Nat. Genet. 40, 719–721. doi:
10.1038/ng.158
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas,
J. R., et al. (2012). Adeno-associated virus serotype 9 transduction in the central
nervous system of nonhuman primates. Hum. Gene Ther. 23, 382–389. doi:
10.1089/hum.2011.200
Simon,M.D., Pinter, S. F., Fang, R., Sarma,K., Rutenberg-Schoenberg,M., Bowman,
S. K., et al. (2013). High-resolution Xist binding maps reveal two-step spreading
during X-chromosome inactivation. Nature. doi: 10.1038/nature12719 [Epub
ahead of print].
Skryabin, B. V., Gubar, L. V., Seeger, B., Pfeiffer, J., Handel, S., Robeck, T.,
et al. (2007). Deletion of the MBII-85 snoRNA gene cluster in mice results in
postnatal growth retardation. PLoS Genet. 3:e235. doi: 10.1371/journal.pgen.
0030235
Smart, F., Aschraﬁ, A., Atkins, A., Owens, G. C., Pilotte, J., Cunningham, B. A.,
et al. (2007). Two isoforms of the cold-inducible mRNA-binding protein RBM3
localize to dendrites and promote translation 6. J. Neurochem. 101, 1367–1379.
doi: 10.1111/j.1471-4159.2007.04521.x
Stenman, J., Toresson, H., and Campbell, K. (2003). Identiﬁcation of two dis-
tinct progenitor populations in the lateral ganglionic eminence: implications for
striatal and olfactory bulb neurogenesis. J. Neuroscience 23, 167–174.
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., et al.
(1992). DNA methylation represses FMR-1 transcription in fragile X syndrome.
Hum. Mol. Genet. 1, 397–400. doi: 10.1093/hmg/1.6.397
Talkowski, M. E., Rosenfeld, J. A., Blumenthal, I., Pillalamarri, V., Chiang, C.,
Heilbut, A., et al. (2012). Sequencing chromosomal abnormalities reveals neu-
rodevelopmental loci that confer risk across diagnostic boundaries. Cell 149,
525–537. doi: 10.1016/j.cell.2012.03.028
Tsai, M.-C., Manor, O., Wan, Y., Mosammaparast, N., Wang, J. K.,
Lan, F., et al. (2010). Long noncoding RNA as modular scaffold of his-
tone modiﬁcation complexes. Science 329, 689–693. doi: 10.1126/science.
1192002
van Bokhoven, H. (2011). Genetic and epigenetic networks in intellectual disabili-
ties. Annu. Rev. Genet. 45, 81–104. doi: 10.1146/annurev-genet-110410-132512
Vincent, J. B., Petek, E., Thevarkunnel, S., Kolozsvari, D., Cheung, J., Patel, M.,
et al. (2002). The RAY1/ST7 tumor-suppressor locus on chromosome 7q31
represents a complex multi-transcript system. Genomics 80, 283–294. doi:
10.1006/geno.2002.6835
Visvanathan, J., Lee, S., Lee, B., Lee, J.W., and Lee, S. K. (2007). ThemicroRNAmiR-
124 antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS
development. Genes Dev. 21, 744–749. doi: 10.1101/gad.1519107
Vite, C. H., Mcgowan, J. C., Niogi, S. N., Passini, M. A., Drobatz, K. J., Haskins,
M. E., et al. (2005). Effective gene therapy for an inherited CNS disease in a large
animal model. Ann. Neurol. 57, 355–364. doi: 10.1002/ana.20392
Vulto-van Silfhout, A. T., De Vries, B. B., Van Bon, B. W., Hoischen, A.,
Ruiterkamp-Versteeg, M., Gilissen, C., et al. (2013). Mutations in MED12
Cause X-Linked Ohdo Syndrome. Am. J. Human Genet. 92, 401–406. doi:
10.1016/j.ajhg.2013.01.007
Wang, J., Zhang, J., Zheng, H., Li, J., Liu, D., Li, H., et al. (2004). Mouse transcrip-
tome: neutral evolution of ‘non-coding’complementary DNAs. Nature 431, 1.
doi: 10.1038/nature03016
Wang, X., Arai, S., Song, X., Reichart, D., Du, K., Pascual, G., et al. (2008). Induced
ncRNAs allostericallymodifyRNA-bindingproteins in cis to inhibit transcription.
Nature 454, 126–130. doi: 10.1038/nature06992
Wang, X., Song, X., Glass, C. K., and Rosenfeld, M. G. (2011). The long arm
of long noncoding RNAs: roles as sensors regulating gene transcriptional pro-
grams. Cold Spring Harb. Perspect. Biol. 3, a003756. doi: 10.1101/cshperspect.
a003756
Wevrick, R., and Francke, U. (1997). An imprintedmouse transcript homologous to
the human imprinted in Prader-Willi syndrome (IPW) gene. Hum. Mol. Genet.
6, 325–332. doi: 10.1093/hmg/6.2.325
Wevrick, R., Kerns, J. A., and Francke, U. (1994). Identiﬁcation of a novel paternally
expressed gene in the Prader-Willi syndrome region. Hum. Mol. Genet. 3, 1877–
1882. doi: 10.1093/hmg/3.10.1877
Willemsen, M. H., Valles, A., Kirkels, L. A., Mastebroek, M., Olde Loohuis, N., Kos,
A., et al. (2011). Chromosome 1p21.3 microdeletions comprising DPYD and
Frontiers in Molecular Neuroscience www.frontiersin.org December 2013 | Volume 6 | Article 53 | 8
“fnmol-06-00053” — 2013/12/26 — 15:15 — page 9 — #9
van De Vondervoort et al. Long non-coding RNAs in neurodevelopmental disorders
MIR137 are associated with intellectual disability. J. Med. Genet. 48, 810–818.
doi: 10.1136/jmedgenet-2011-100294
Willingham, A. T., Orth, A. P., Batalov, S., Peters, E. C., Wen, B. G., Aza-Blanc,
P., et al. (2005). A strategy for probing the function of noncoding RNAs ﬁnds a
repressor of NFAT. Science 309, 1570–1573. doi: 10.1126/science.1115901
Yakovchuk, P., Goodrich, J. A., and Kugel, J. F. (2009). B2 RNA and Alu RNA repress
transcription by disrupting contacts between RNA polymerase II and promoter
DNA within assembled complexes. Proc. Natl. Acad. Sci. U.S.A. 106, 5569–5574.
doi: 10.1073/pnas.0810738106
Zalfa, F., Adinolﬁ, S., Napoli, I., Kuhn-Holsken, E., Urlaub, H., Achsel, T., et al.
(2005). Fragile X mental retardation protein (FMRP) binds speciﬁcally to the
brain cytoplasmic RNAs BC1/BC200 via a novel RNA-binding motif. J. Biol.
Chem. 280, 33403–33410. doi: 10.1074/jbc.M504286200
Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., et al. (2003).
The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the
translation of speciﬁcmRNAs at synapses.Cell 112, 317–327. doi: 10.1016/S0092-
8674(03)00079-5
Zhang, B., Arun, G., Mao, Y. S., Lazar, Z., Hung, G., Bhattacharjee, G., et al.
(2012). The lncRNA Malat1 is dispensable for mouse development but its tran-
scription plays a cis-regulatory role in the adult. Cell Rep. 2, 111–123. doi:
10.1016/j.celrep.2012.06.003
Zhao, J., Sun, B. K., Erwin, J. A., Song, J.-J., and Lee, J. T. (2008). Polycomb
proteins targeted by a short repeat RNA to the mouse X chromosome. Science
322, 750–756. doi: 10.1126/science.1163045
Ziats, M. N., and Rennert, O. M. (2013). Aberrant expression of long noncoding
RNAs in autistic brain. J. Mol. Neurosci. 49, 589–593. doi: 10.1007/s12031-012-
9880-8
Zoghbi, H. Y. (2003). Postnatal neurodevelopmental disorders: meeting at the
synapse? Science 302, 826–830. doi: 10.1126/science.1089071
Conflict of Interest Statement:The authors declare that the researchwas conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 29 July 2013; accepted: 09 December 2013; published online: 30 December
2013.
Citation: van de Vondervoort IIGM, Gordebeke PM, Khoshab N, Tiesinga PHE, Buite-
laar JK, Kozicz T, Aschraﬁ A and Glennon JC (2013) Long non-coding RNAs in
neurodevelopmental disorders. Front. Mol. Neurosci. 6:53. doi: 10.3389/fnmol.2013.
00053
This article was submitted to the journal Frontiers in Molecular Neuroscience.
Copyright © 2013 van de Vondervoort, Gordebeke, Khoshab, Tiesinga, Buitelaar, Koz-
icz, Aschraﬁ and Glennon. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Molecular Neuroscience www.frontiersin.org December 2013 | Volume 6 | Article 53 | 9
